Moderna $MRNA is now the best performer in the S&P 500 for 2026, up 667%. That's not a typo—a near 7x move year-to-date. Something major shifted in the biotech narrative or pipeline to fuel this kind of run. Worth watching if this momentum holds or if profit-taking starts creeping in.